Katharine C Lai Selected Research

naratuximab emtansine

9/2017	The Antitumor Activity of IMGN529, a CD37-Targeting Antibody-Drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma Models.
11/2013	A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Katharine C Lai Research Topics

Disease

9	Neoplasms (Cancer) 01/2021 - 03/2010
2	Lymphoma (Lymphomas) 01/2019 - 11/2013
2	Non-Hodgkin Lymphoma (Lymphosarcoma) 09/2017 - 11/2013
1	Colorectal Neoplasms (Colorectal Cancer) 10/2020
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2019
1	Leukemia 01/2019
1	B-Cell Lymphoma (Lymphoma, B Cell) 01/2019
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2018
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 09/2017
1	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 11/2013
1	Colonic Neoplasms (Colon Cancer) 04/2011

Drug/Important Bio-Agent (IBA)

6	Immunoconjugates (Immunoconjugate)IBA 01/2021 - 11/2013
3	AntigensIBA 01/2021 - 03/2010
2	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 01/2018
2	Rituximab (Mabthera)FDA Link 09/2017 - 11/2013
2	naratuximab emtansineIBA 09/2017 - 11/2013
1	auristatinIBA 10/2020
1	indusatumabIBA 10/2020
1	coltuximab ravtansineIBA 01/2019
1	Cytotoxins (Cytolysins)IBA 01/2018
1	Alkylating AgentsIBA 01/2018
1	Differentiation AntigensIBA 01/2018
1	Peptides (Polypeptides)IBA 01/2016
1	Epithelial Cell Adhesion MoleculeIBA 01/2016
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 11/2013
1	Bendamustine Hydrochloride FDA Link 11/2013
1	Prednisone (Sone)FDA LinkGeneric 11/2013
1	Vincristine (Oncovin)FDA LinkGeneric 11/2013
1	DisulfidesIBA 04/2011
1	AntibodiesIBA 03/2010

Therapy/Procedure

1	Intravenous Administration 10/2020